Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
x091rGzqc9M6MDdQ
Listen
